Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year?

Company Performance - Solventum (SOLV) has shown a year-to-date performance increase of approximately 21.2%, outperforming the average gain of 7.9% in the Medical sector [4] - The Zacks Consensus Estimate for Solventum's full-year earnings has increased by 1.6% over the past three months, indicating improving analyst sentiment [3] - Solventum holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the stock [3] Industry Comparison - Solventum is part of the Medical Services industry, which consists of 62 companies and currently ranks 160 in the Zacks Industry Rank [5] - The Medical Services industry has seen an average gain of 7.6% year-to-date, with Solventum outperforming this group [5] - In contrast, Cronos Group (CRON), another Medical stock, has returned 31.7% year-to-date and belongs to the Medical - Drugs industry, which ranks 82 and has increased by 8.4% [4][6]